In Vivo CAR Vector Biosafety Testing | HyQure

In Vivo CAR Safety Testing

Vector biosafety, replication-competent virus control, contaminant testing, and in vivo biosafety support for direct in vivo programming strategies.

Request a Quote Contact a Scientific Project Manager

Modality > Cell & Gene Therapy (CGT) > In Vivo CAR Safety Testing

Program Overview

In vivo CAR programs can raise complex vector-biosafety, contaminant-control, and matrix-specific testing questions. This service focus centers on supported biosafety pathways such as RCV or rcAAV testing, viral contaminant testing, residual DNA/RNA support, microbial testing, qPCR/ddPCR/NGS and TEM-enabled methods, in-vitro or in-vivo virus testing, and tumorigenicity-related studies where the risk assessment requires them.

Why HyQure - Advantages

RCV and vector-biosafety pathways

RCL, RCR, RCA, and rcAAV risk-control pathways, together with AAV-related biosafety elements where relevant to the vector system, form the core vector-biosafety story on this page.
Contaminant and impurity control

Residual DNA/RNA support, viral contaminant qPCR panels, mycoplasma, endotoxin support, and other biosafety assays help answer matrix-specific safety questions.
In vitro and in vivo virus-testing capability

HyQure's capability set includes in vitro virus testing, in vivo inoculation models, MAP/HAP/RAP pathways, embryonated-egg methods, and related investigations when justified by program risk.
Molecular and imaging-enabled methods

qPCR, NGS, TEM, and controlled data systems can be used as supporting platforms for biosafety investigations and sponsor-facing reporting. Accelerated mycoplasma and sterility tests (5–7 days) keep your in vivo therapy program on track for on-time IND submissions.

Supported Testing Pathways

Replication-competent virus and AAV risk control

RCL, RCR, RCA, rcAAV, and related vector-biosafety testing for relevant matrices and development stages.
Viral contaminant and residual nucleic-acid testing

qPCR/ddPCR-based contaminant testing, residual DNA/RNA support, and method-validation pathways for vector- or matrix-specific questions.
In vitro / in vivo virus testing

In vitro assay coverage plus in vivo virus-testing capability including MAP/HAP/RAP, inoculation models, and related biosafety investigations.
Tumorigenicity / oncogenicity and related studies

Tumorigenicity or oncogenicity investigations may be supported where they are justified by program design and confirmed during technical scoping.

Sample requirements and Deliverables

Program entry samples

Vector drug substance or drug product, MCB/MVB, process intermediates, cell substrates, and biosafety-investigation samples confirmed during scoping.

Scope confirmation

Matrix, volume, transport conditions, and whether the question is RCV-, contaminant-, in vivo-virus-, or tumorigenicity-related should be defined before study start.

Key deliverables

Technical reports, method-validation files where applicable, sponsor-facing biosafety summaries, and documentation packages prepared for quality review.

Study alignment

Product-specific study design should be confirmed early when the development question goes beyond routine vector biosafety or contaminant control.